Cirrhosis/Liver Failure News

The FDA granted fast track designation to ARO-AAT, Arrowhead Pharmaceuticals’ second generation subcutaneously administered RNA interference therapeutic, for the treatment of alpha-1 antitrypsin deficiency-related liver disease, according to a press release.

Cirrhosis, or late stage fibrosis, can result from a variety of causes including progression from nonalcoholic fatty liver disease and very often from alcohol-related liver disease. Without care from a physician, this can lead to end-stage liver disease and organ failure.

Patients with central obesity, insulin resistance and active psoriasis are at high risk for liver fibrosis, according to researchers from King’s College London.

Treatment with high-dose levels of albumin reduced systemic inflammation and cardiocirculatory dysfunction in patients with decompensated cirrhosis, according to an analysis published in Gastroenterology.

Mallinckrodt achieved target enrollment of 300 participants for a phase 3 clinical study designed to evaluate the safety and efficacy of terlipressin for patients with hepatorenal syndrome type 1, according to a press release.

Durect Corporation announced preliminary data from an ongoing phase 2a trial of DUR-928 for alcohol-related hepatitis, according to a press release.

Patients with cirrhosis had improved quality of care and outcomes when treated by advanced practice providers compared with those without such care.

Although the prevalence of alcoholic fatty liver disease among U.S. adults remained stable between 2001 and 2016, the prevalence of those with stage 2 or higher fibrosis increased significantly, according to a study published in JAMA.

Early alcohol rehabilitation reduced 30-day readmission, alcohol relapse and mortality among patients hospitalized for alcohol-related hepatitis, according to data published in Clinical Gastroenterology and Hepatology.

VIENNA — Researchers reported an increasing prevalence of alcoholic cirrhosis in a large representative Canadian population, especially among middle-aged men, according to a presentation at the International Liver Congress 2019.